Clinical Microbiology and Infection最新文献

筛选
英文 中文
Detection of Borrelia burgdorferi sensu lato by proteomics: a complementary diagnosis tool on erythema migrans biopsies. 通过蛋白质组学检测包柔氏菌:偏头痛红斑活检的辅助诊断工具。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-23 DOI: 10.1016/j.cmi.2024.10.014
Paola Cantero, Laurence Ehret-Sabatier, Cédric Lenormand, Yves Hansmann, Erik Sauleau, Laurence Zilliox, Benoit Westermann, Benoit Jaulhac, Didier Mutter, Cathy Barthel, Pauline Perdu-Alloy, Martin Martinot, Dan Lipsker, Nathalie Boulanger
{"title":"Detection of Borrelia burgdorferi sensu lato by proteomics: a complementary diagnosis tool on erythema migrans biopsies.","authors":"Paola Cantero, Laurence Ehret-Sabatier, Cédric Lenormand, Yves Hansmann, Erik Sauleau, Laurence Zilliox, Benoit Westermann, Benoit Jaulhac, Didier Mutter, Cathy Barthel, Pauline Perdu-Alloy, Martin Martinot, Dan Lipsker, Nathalie Boulanger","doi":"10.1016/j.cmi.2024.10.014","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.014","url":null,"abstract":"<p><strong>Objectives: </strong>We have developed targeted proteomics in the context of Lyme borreliosis as a new direct diagnostic tool for detecting Borrelia proteins in the skin of patients with erythema migrans. If satisfactory, this proteomic technique could be used in addition to culture and/or PCR for disseminated infections, where Borrelia detection is essential to demonstrate active infection. In these infections, diagnosis is indirect and relies mainly on serology.</p><p><strong>Methods: </strong>We recruited 46 patients with Lyme borreliosis and 11 controls and collected two skin biopsies from each patient. One biopsy was used for B. burgdorferi sensu lato PCR and culture and the other one was for targeted mass-spectrometry based proteomics. Six markers of infection were selected for proteomics: OspC, flagellin, enolase, lipoprotein gi|365823350, DpbA, and GAPDH.</p><p><strong>Results: </strong>Culturing Borrelia from the biopsies increased the sensitivity of the methods. Among the patients included for analysis, 61% (28 patients), 61% (28), and 46% (21) were detected as positive, by proteomics, PCR, and culture respectively. PCR and proteomics were complementary. OspC and flagellin were the most frequently detected protein markers of infection by proteomics, which in some patients, detected up to 9 peptides for the flagellin.</p><p><strong>Conclusions: </strong>It is possible to identify bacterial makers from the skin by proteomics. Our approach can be used to diagnose tick-borne diseases such as Lyme borreliosis.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02414789.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: 'Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study' by Walt et al. 关于Walt 等人撰写的 "一项多队列研究中对 SARS-CoV-2 感染后循环病毒抗原的测量"。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-23 DOI: 10.1016/j.cmi.2024.10.018
Guangting Zeng
{"title":"Re: 'Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study' by Walt et al.","authors":"Guangting Zeng","doi":"10.1016/j.cmi.2024.10.018","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.018","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants: a COVI-PREG prospective cohort study. 与未暴露的婴儿相比,子宫内暴露于 SARS-CoV-2 或 mRNA COVID-19 疫苗的婴儿的神经发育结果:COVI-PREG 前瞻性队列研究。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-23 DOI: 10.1016/j.cmi.2024.10.019
Guillaume Favre, Rebecca L Bromley, Matthew Bluett-Duncan, Emeline Maisonneuve, Léo Pomar, Charlotte Daire, Anda-Petronela Radan, Luigi Raio, Daniel Surbek, Carolin Blume, Stylianos Kalimeris, Yoann Madec, Juliane Schneider, Myriam Bickle Graz, Ursula Winterfeld, Alice Panchaud, David Baud
{"title":"Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA COVID-19 vaccine compared to unexposed infants: a COVI-PREG prospective cohort study.","authors":"Guillaume Favre, Rebecca L Bromley, Matthew Bluett-Duncan, Emeline Maisonneuve, Léo Pomar, Charlotte Daire, Anda-Petronela Radan, Luigi Raio, Daniel Surbek, Carolin Blume, Stylianos Kalimeris, Yoann Madec, Juliane Schneider, Myriam Bickle Graz, Ursula Winterfeld, Alice Panchaud, David Baud","doi":"10.1016/j.cmi.2024.10.019","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.019","url":null,"abstract":"<p><strong>Objectives: </strong>Data are lacking regarding the long-term consequences of SARS-CoV-2 and COVID-19 mRNA vaccine on infants exposed in utero. We aimed to evaluate the neurodevelopment of infants exposed prenatally to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy at 12 months after birth.</p><p><strong>Methods: </strong>Infants born from mothers exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy, or unexposed to either the virus or the vaccine were enrolled from 2021 to 2023. Infants with prenatal exposure to the virus or vaccine were compared to infants without prenatal exposure to the virus and/or vaccine. Parents received a neurodevelopmental questionnaire (ASQ-3) at 12 months after birth assessing 5 subdomains: communication, gross motor, fine motor, problem solving and personal social development. A low score was defined as <2 standard deviations below the normative mean in at least one of the subdomains.</p><p><strong>Results: </strong>A total of 330 infants were included (76 in the SARS-CoV-2 group; 153 in the mRNA-COVID-19 vaccine group; 101 in the reference group). In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine were not associated with an increased risk of a low score for at least one subdomain compared to the reference group. The crude odds ratios were 1.16 (95% confidence interval [CI] 0.59-2.28) and 1.04 (95% CI 0.58-1.86), respectively. Results remained consistent in the multivariate analysis, showing no increased risk of a low score for at least one subdomain for infants exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine, compared to the reference group. The adjusted odds ratios were 1.74 (95% CI 0.76-3.99) and 0.76 (95% CI 0.39-1.49), respectively.</p><p><strong>Conclusion: </strong>In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one ASQ-3 subdomain at 12 months after birth. Additional studies are needed to confirm our results, especially longer-term evaluation of infant development.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infections in immunocompromised hosts: progress made and challenges ahead. 免疫力低下宿主的感染:取得的进展和面临的挑战。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-22 DOI: 10.1016/j.cmi.2024.10.017
Joseph Sassine, Chrysanthi Skevaki, Roy F Chemaly
{"title":"Infections in immunocompromised hosts: progress made and challenges ahead.","authors":"Joseph Sassine, Chrysanthi Skevaki, Roy F Chemaly","doi":"10.1016/j.cmi.2024.10.017","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.017","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates. 舒巴坦-杜鲁巴坦对产生 NDM 的大肠埃希菌(包括头孢克肟和阿曲南类阿维菌素耐药分离株)具有强效体外活性。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-22 DOI: 10.1016/j.cmi.2024.10.012
Christophe Le Terrier, Patrice Nordmann, Adam Delaval, Laurent Poirel
{"title":"Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates.","authors":"Christophe Le Terrier, Patrice Nordmann, Adam Delaval, Laurent Poirel","doi":"10.1016/j.cmi.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.012","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"HANCEK" Infective Endocarditis: A Case for Including Neisseria elongata in the HACEK Group. "HACEK "感染性心内膜炎:将细长奈瑟菌纳入 HACEK 组的案例。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-22 DOI: 10.1016/j.cmi.2024.10.015
Brandon J Webb, Mark A Fisher, Nick Tinker
{"title":"\"HANCEK\" Infective Endocarditis: A Case for Including Neisseria elongata in the HACEK Group.","authors":"Brandon J Webb, Mark A Fisher, Nick Tinker","doi":"10.1016/j.cmi.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.015","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomised, multicentre, open-label, superiority clinical trial. 延长输注β-内酰胺类抗生素治疗血液病患者发热性中性粒细胞减少症的疗效(BEATLE):一项随机、多中心、开放标签、优势临床试验。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-19 DOI: 10.1016/j.cmi.2024.10.006
Julia Laporte-Amargos, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Raul Rigo-Bonnin, Marta Ulldemolins, Montserrat Arnan, Jose Luis Del Pozo, Anna Torrent, Carolina Garcia-Vidal, Natàlia Pallarès, Cristian Tebé, Carme Muñoz, Fe Tubau, Ariadna Padullés, Ana-Maria Sureda, Jordi Carratalà, Carlota Gudiol
{"title":"Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomised, multicentre, open-label, superiority clinical trial.","authors":"Julia Laporte-Amargos, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Raul Rigo-Bonnin, Marta Ulldemolins, Montserrat Arnan, Jose Luis Del Pozo, Anna Torrent, Carolina Garcia-Vidal, Natàlia Pallarès, Cristian Tebé, Carme Muñoz, Fe Tubau, Ariadna Padullés, Ana-Maria Sureda, Jordi Carratalà, Carlota Gudiol","doi":"10.1016/j.cmi.2024.10.006","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.006","url":null,"abstract":"<p><strong>Objectives: </strong>The efficacy of extended infusions (EI) of β-lactam antibiotics for optimising outcomes in febrile neutropenia is unclear. We assessed whether the administration of β-lactams was more effective in EI than in intermittent infusion (II) for the treatment of febrile neutropenia.</p><p><strong>Methods: </strong>We performed a randomised, open-label, superiority clinical trial of patients with febrile neutropenia at four Spanish university hospitals. Patients undergoing haematopoietic stem cell transplantation or with acute leukaemia receiving chemotherapy who required empirical antibiotic treatment for febrile neutropenia were randomly assigned (1:1) to receive EI of β-lactam or II after a first dose in bolus. The choice of antipseudomonal β-lactam was left to the discretion of the attending physician. The primary endpoint was treatment success at day 5, defined as defervescence without modifying the antibiotic treatment. Secondary endpoints included adverse events, attainment of the pharmacokinetic/pharmacodynamic target of 50, 75 and 100%ƒ<sub>u</sub>T<sub>>MIC</sub>, and 30-day mortality.</p><p><strong>Results: </strong>Between November 19, 2019 and June 22, 2022, 295 patients we screened for eligibility, of whom 150 were randomly assigned to receive EI (n=77) or II (n=73) of the antipseudomonal β-lactam of choice. In the intention-to-treat analysis, treatment success at day 5 was achieved in 39/77 patients (50.6%) receiving EI versus 46/73 patients (63.0%) receiving II (risk difference -12.4%; 95% confidence interval, -29.4 to 4.7, p=0.17). The pharmacokinetic/pharmacodynamic targets of 75 and 100% ƒ<sub>u</sub>T<sub>>MIC</sub> for empirical treatment were achieved more frequently in the EI group. No statistically-significant differences were found between groups in terms of adverse events or 30-day mortality.</p><p><strong>Conclusions: </strong>Our findings do not support the routine use of empirical EI of β-lactams in febrile neutropenia. Further studies should consider the clinical heterogeneity of febrile neutropenia and focus on patients with sepsis/septic shock and microbiologically documented infections, particularly those with infections caused by microorganisms less susceptible to β-lactams.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Why don't we talk about Tuberculosis stewardship?" "我们为什么不谈谈结核病管理?"
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-19 DOI: 10.1016/j.cmi.2024.10.013
Niccolò Riccardi, Tommaso Matucci, Marco Falcone
{"title":"\"Why don't we talk about Tuberculosis stewardship?\"","authors":"Niccolò Riccardi, Tommaso Matucci, Marco Falcone","doi":"10.1016/j.cmi.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.013","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elucidating the role of internal migration in the spread of M. tuberculosis. 阐明国内迁移在结核杆菌传播中的作用。
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-19 DOI: 10.1016/j.cmi.2024.10.011
Kesia Esther Da Silva, Jason R Andrews
{"title":"Elucidating the role of internal migration in the spread of M. tuberculosis.","authors":"Kesia Esther Da Silva, Jason R Andrews","doi":"10.1016/j.cmi.2024.10.011","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.011","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Candida auris MIC testing by EUCAST and CLSI broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant? 通过 EUCAST 和 CLSI 肉汤微量稀释及梯度扩散条进行的念珠菌 MIC 检测;对两性霉素 B 是否耐药?
IF 10.9 1区 医学
Clinical Microbiology and Infection Pub Date : 2024-10-17 DOI: 10.1016/j.cmi.2024.10.010
Maiken Cavling Arendrup, Shawn R Lockhart, Nathan Wiederhold
{"title":"Candida auris MIC testing by EUCAST and CLSI broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant?","authors":"Maiken Cavling Arendrup, Shawn R Lockhart, Nathan Wiederhold","doi":"10.1016/j.cmi.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.cmi.2024.10.010","url":null,"abstract":"<p><strong>Objectives: </strong>Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing or adoption of a clinical breakpoint (BP) that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection.</p><p><strong>Methods: </strong>Forty C. auris strains from nine US states and ≥3 clades were included. Fourteen MIC data sets were generated using EUCAST E.Def 7.4, CLSI M27Ed4, Etest and MTS (Liofilchem) strip MICs. MICs ≤1 mg/L were classified as susceptible.</p><p><strong>Results: </strong>EUCAST and CLSI amphotericin B MIC testing were robust across included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar GM-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest and MTS strip MICs correlated to the OD of drug-free control EUCAST wells suggesting that some isolates grew better than others and that this was associated with MIC.</p><p><strong>Conclusions: </strong>The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggest the current breakpoint leads to random susceptibility classification.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信